ANKHD1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in the Jurkat human T lymphocyte line, produced by disruption of the ANKHD1 gene. This product consists of a heterogeneous pool of cells bearing loss-of-function edits, preserving genetic diversity while ensuring effective gene disruption for pooled functional screens and high-throughput applications.
The Jurkat cell line (clone E6-1) is an immortalized CD4+ T lymphocyte line derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. Jurkat cells are a widely used model for T cell receptor signaling, apoptosis, and HIV infection, and they provide a disease-relevant background for studying T-cell malignancies.
ANKHD1 (Ankyrin Repeat and KH Domain Containing 1) encodes an RNA-binding protein that orchestrates post-transcriptional gene regulation through sequence-specific RNA interactions, mediating mRNA stability and translation. It contains multiple ankyrin repeats and a KH domain. Upstream signals including MYC and NOTCH1 regulate ANKHD1, while it directly or indirectly controls expression of key cell cycle and apoptosis regulators such as CCND1, CDK4, and BCL2, and binds MYC mRNA. ANKHD1 interacts with YBX1 and translational machinery components to influence protein synthesis. Its disruption destabilizes these targets, impairing cell cycle progression and sensitizing cells to apoptotic cues.
In Jurkat cells, ANKHD1 knockout creates a valuable loss-of-function model to dissect the role of RNA-binding proteins in T-cell acute lymphoblastic leukemia (T-ALL) pathogenesis. Given the origin from a T-ALL patient, these polyclonal knockout cells recapitulate a disease-relevant cellular environment where ANKHD1 may contribute to aberrant proliferation and survival signaling. The model facilitates examination of how post-transcriptional dysregulation drives leukemogenesis, and it enables comparative studies between wild-type and ANKHD1-disrupted populations to identify therapeutic vulnerabilities.
Research applications for ANKHD1 Knockout Jurkat Polyclonal Cells include functional genomics studies of RNA-binding proteins in T-cell leukemia, drug screening to identify novel therapeutics, and detailed analysis of apoptosis and proliferation pathways. These cells are compatible with a range of techniques: RT-qPCR and Western blotting for gene and protein expression profiling, RNA immunoprecipitation to map RNA-protein interactions, flow cytometry to measure apoptosis, MTT assays for proliferation, as well as RNA-seq and polysome profiling for transcriptome-wide and translational studies. For further details or customization options, please contact Ascent Research.
